Mortality Evidence for Stopping Statins After Age 75

The mortality finding in context

Adults aged 75 or older who had no prior atherosclerotic cardiovascular disease were randomized either to discontinue a statin used for primary prevention or to continue treatment. Over three years, discontinuation was reported as noninferior to continuation for all-cause mortality.

That finding matters because evidence about starting or continuing preventive statin therapy becomes less certain at advanced ages. Older adults are also more likely to face polypharmacy, treatment burden, competing causes of death, frailty, adverse effects and changing goals of care. A randomized comparison of stopping versus continuing therefore addresses a question that initiation trials do not answer directly.

Noninferiority does not establish that the two strategies are identical. It means the trial’s confidence interval excluded a prespecified amount of excess mortality considered clinically unacceptable. The exact mortality rates in each arm, effect estimate, confidence interval and noninferiority margin must be considered together before deciding how reassuring the result is.

Those numerical details cannot safely be reconstructed from the source summary supplied for this brief. The linked PubMed record is the authoritative source for the enrolled sample size, arm-level deaths, effect measure, confidence interval, analysis population and margin. Verify these details in the final article before using the result in a protocol, guideline, or patient-facing decision aid.

How to read a noninferiority result

The point estimate is only the trial’s best estimate of the relative or absolute mortality effect. The confidence interval describes the range of effects reasonably compatible with the observed data under the statistical model. For deprescribing, the clinically important question is not simply whether the interval crosses the null; it is how much excess mortality remains possible at its unfavorable boundary.

Suppose an estimate favors discontinuation but its confidence interval extends toward modest harm. The trial may still meet its formal noninferiority criterion if the entire interval remains within the prespecified margin. Clinicians and patients may nevertheless judge the residual possibility of harm differently, particularly when baseline cardiovascular risk is high or avoiding myocardial infarction and stroke is a major priority.

The noninferiority margin deserves equal scrutiny. It should represent a loss of benefit that patients and clinicians would accept in exchange for advantages such as lower pill burden, fewer medication-related symptoms, reduced cost or simpler care. A statistically valid margin can still be clinically unpersuasive if it permits more excess mortality than a patient considers acceptable.

Absolute risk is usually easier to discuss than a relative measure. Arm-level mortality percentages and their absolute difference show how many additional or fewer deaths occurred per 100 treated people during three years. Relative risks or hazard ratios can complement that information, but they should not replace it. If the trial reports both intention-to-treat and per-protocol analyses, agreement between them strengthens a noninferiority interpretation because treatment crossover and nonadherence can make groups appear artificially similar.

Follow-up also sets a firm boundary. Three-year noninferiority does not establish equivalent outcomes over five or 10 years. Statins may prevent nonfatal cardiovascular events before they affect all-cause mortality, and an all-cause mortality endpoint can obscure offsetting changes in cardiovascular and noncardiovascular deaths.

Using the evidence in deprescribing conversations

The result supports considering discontinuation as an evidence-based option for adults who resemble the trial population: people aged at least 75 years taking statins solely for primary prevention. It does not make discontinuation the default, and it does not apply automatically to anyone with prior myocardial infarction, ischemic stroke, symptomatic peripheral artery disease or another established form of ASCVD.

A useful discussion begins by confirming why the statin was prescribed. Medical records may be incomplete, and a medication labeled “preventive” may actually have followed a vascular event or imaging finding. The conversation can then address baseline cardiovascular risk, life expectancy, frailty, medication burden, suspected adverse effects and the outcomes the person values most.

The mortality estimate should be presented with its confidence interval in plain language. Rather than saying that stopping is “just as safe,” a more accurate explanation is that the trial ruled out the prespecified degree of excess 3-year mortality, while smaller benefit or harm remained statistically possible. The unfavorable end of the interval can then be compared with the patient’s tolerance for uncertainty.

Potential benefits of stopping should also be made explicit rather than assumed. They may include one fewer daily medicine, less monitoring or concern about medication effects, and a chance to assess whether nonspecific symptoms improve. The trial’s mortality result alone does not prove improvements in cognition, muscle symptoms, function or quality of life; those outcomes require their own data.

US guidance provides important context but not a substitute for this trial. The 2018 cholesterol guideline emphasized clinician–patient discussion for people older than 75 because randomized evidence was limited. The US Preventive Services Task Force subsequently concluded that evidence was insufficient to assess the balance of benefits and harms of initiating statins for primary prevention in adults 76 or older. Initiation and discontinuation are different decisions, however, and recommendations about starting therapy should not be treated as evidence that stopping established therapy is harmless.

Where uncertainty remains

The central limitation is duration. Three years may be highly relevant for people with limited life expectancy or substantial treatment burden, but it may not capture the full consequences for healthy adults likely to live much longer. Mortality is also only one outcome. Cardiovascular death, myocardial infarction, stroke, revascularization, function, cognition, quality of life and medication-related symptoms may influence decisions even when all-cause mortality is noninferior.

Generalizability depends on who was enrolled. Trial participants may differ from patients with severe frailty, advanced multimorbidity, very high low-density lipoprotein cholesterol, diabetes, chronic kidney disease or unusually high coronary risk. The specific statins and treatment intensities used before randomization also matter. Subgroup findings, if reported, should be treated cautiously unless they were prespecified and adequately powered.

Noninferiority trials are especially sensitive to adherence, crossover, missing outcome data and the chosen margin. Funding and author conflicts should also be reviewed in the full publication. Until the exact sample size, event counts, confidence interval and margin have been checked against the article, the defensible conclusion is limited: discontinuation met the trial’s formal 3-year mortality criterion in the studied population, not that stopping statins carries no risk.

Questions clinicians ask

Does this trial show that statins provide no benefit after age 75?

No. It tested discontinuation among older adults already taking statins for primary prevention and evaluated 3-year all-cause mortality. It does not establish that statins have no effect on myocardial infarction, stroke or longer-term mortality, and it should not be extrapolated to secondary prevention.

What part of the confidence interval matters most?

For a deprescribing decision, focus on the boundary compatible with the greatest harm from stopping. Compare that boundary with the prespecified noninferiority margin and with the amount of excess absolute mortality the patient would accept in exchange for reduced treatment burden.

Can the finding be applied to a patient with previous ASCVD?

No. The population was defined by the absence of prior ASCVD and statin use for primary prevention. Evidence from this trial should not be used to justify discontinuation when a statin is being prescribed for secondary prevention after an established cardiovascular event or diagnosis.

Does the result support automatic deprescribing at age 75?

No. Chronologic age alone does not determine cardiovascular risk, life expectancy, treatment burden or preferences. The evidence supports offering discontinuation as a discussable option for eligible adults, with the trial’s absolute mortality estimate, confidence interval, follow-up period and remaining outcome uncertainties made clear.

References

1. Discontinuation of statins for primary prevention in adults ≥75 years is non-inferior to continuation over 3 years — PubMed, 2026 2. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary — PubMed, 2019 3. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease — PubMed, 2019 4. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement — PubMed, 2022